✨ Unlock Unlimited Data Exports & Disclosures Access with Tracenable Pro. Learn More →

Halozyme Therapeutics Inc

Common Name
Halozyme Therapeutics
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
350
Ticker
HALO
Exchange
NASDAQ/NGS
Description
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary techno...

Halozyme Therapeutics's Financial Statements Preview

Below are the financial statements of Halozyme Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of USD
2024
2023
2022
Revenues
Royalties
570.99a
447.87a
360.48a
Product sales, net
303.49a
300.85a
191.03a
Revenues under collaborative agreements
140.84a
80.53a
108.61a
Total revenues
1,015.32a
829.25a
660.12a
Operating expenses
Cost of sales
-159.42a
-192.36a
-139.3a
Amortization of intangibles
-71.05a
-73.77a
-43.15a
Research and development
-79.05a
-76.36a
-66.61a
Selling, general and administrative
-154.34a
-149.18a
-143.53a
Total operating expenses
-463.85a
-491.68a
-392.59a
Operating income
551.48a
337.57a
267.53a
Other income (expense)
Investment and other income, net
23.75a
16.32a
1.05a
Inducement expense related to convertible notes
0a
0a
-2.71a
Contingent liability fair value measurement gain
0a
13.2a
0a
Interest expense
-18.1a
-18.76a
-16.95a
Income before income tax expense
557.13a
348.33a
248.92a
Income tax expense
-113.04a
-66.74a
-46.79a
Net income
444.09a
281.59a
202.13a
Limited Data Preview
You are viewing a limited preview of Halozyme Therapeutics’s income statement data. The reported financial values are complete. The full dataset, available for download, additionally includes structured metadata for each line item, such as line item role (line item, subtotal, total) and financial classification (e.g., assets, liabilities, equity, revenue, expenses).
Unrestricted Access to Data and Sources
pro
Remove manual data sourcing from your workflow. Upgrade to Tracenable Pro for unrestricted access to datasets and disclosures across 8,500+ companies with over 10 years of historical coverage.
Download complete datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace values back to original sources
Formats Included
Excel
CSV
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research

Verified Sources Behind Halozyme Therapeutics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Halozyme Therapeutics’s data sources below and access millions more through our Disclosure Search.

a. Halozyme Therapeutics's 10-K 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?